GC Medical Science녹십자엠에스
142280 · KOSDAQ · ₩142280 · 녹십자엠에스
₩3,395▲ ₩115 (3.51%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 13.4% | 14.0% | 14.3% | 14.9% | 11.3% | 1.6% |
| Operating margin | 2.3% | 2.7% | 2.2% | 1.9% | −1.1% | −19.8% |
| Net margin | −2.1% | 3.4% | 3.4% | 1.9% | −3.2% | −20.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −5.8% | +4.4% | +10.5% | −16.9% | +11.2% | — |
| Operating income growth | −18.0% | +23.7% | +29.7% | +242.6% | +93.7% | — |
| Net income growth | −159.0% | +2.4% | +99.2% | +150.2% | +83.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −4.4% | 8.6% | 9.5% | 5.3% | −10.3% | −58.7% |
| Return on assets | −2.2% | 3.9% | 3.8% | 2.0% | −3.2% | −22.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 72.9% | 95.2% | 102.6% | 145.2% | 170.6% | 152.1% |
| Net debt to equity | 15.0% | 22.0% | −1.6% | −15.6% | 18.0% | 73.4% |
| Current ratio | 146.9% | 115.1% | 106.2% | 93.2% | 127.0% | 107.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: GC Medical Science / 녹십자엠에스 / 142280 / KRX:142280
Source: KRX statistical information